Cargando…
Effectiveness of Messenger Ribonucleic Acid Vaccine in Lung Transplant Recipients
PURPOSE: Immunization is heralded as a key tool to combat the COVID-19 pandemic. One key technology, messenger RNA (mRNA) vaccines have demonstrated an efficacy greater than 94%(1,2). While mRNA vaccines create strong protection in the majority of patients, the antibody response in solid organ recip...
Autores principales: | Vender, R.J., Lashari, B.H., Criner, G.J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988645/ http://dx.doi.org/10.1016/j.healun.2022.01.1333 |
Ejemplares similares
-
Lung cancer in recipients after lung transplant: single-centre experience and literature review
por: Lashari, Bilal Haider, et al.
Publicado: (2022) -
Messenger ribonucleic acid vaccine-associated immune thrombocytopenia: A rare complication of vaccine
por: Islamoglu, Mehmet Sami, et al.
Publicado: (2022) -
Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents
por: Schauer, Jenna, et al.
Publicado: (2021) -
Fulminant Myocarditis 24 Days after Coronavirus Disease Messenger Ribonucleic Acid Vaccination
por: Kawano, Hiroaki, et al.
Publicado: (2022) -
Messenger ribonucleic acid vaccines against infectious
diseases: current concepts and future prospects
por: Edwards, Darin K, et al.
Publicado: (2022)